- Conditions
- Hypertension
- Interventions
- Para-aminohippuric Acid, Angiotensin II, Norepinephrine
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2020
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 169–192
of 15,928
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Acute Myeloid Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Promyelocytic Leukemia (M3), Recurrent Adult Acute Myeloid Leukemia
- Interventions
- clofarabine, cytarabine, filgrastim
- Drug · Biological
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2015
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- HER2-positive Breast Cancer, Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
- Interventions
- trastuzumab, ixabepilone, carboplatin, laboratory biomarker analysis
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Prostate Cancer
- Interventions
- Neoadjuvant Hormonal Therapy, Docetaxel
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Male only
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2015
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Small Cell Lung Cancer
- Interventions
- pemetrexed, etoposide, carboplatin
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 908 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 54
- States / cities
- Huntsville, Alabama • Anchorage, Alaska • Fayetteville, Arkansas + 51 more
- Conditions
- Menopausal Syndrome
- Interventions
- Estradiol (E2), Progesterone (P10) x90, Progesterone (P10) x10
- Drug
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 45 Years to 55 Years · Female only
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Basal Cell Carcinoma of the Skin, Eccrine Carcinoma of the Skin, Recurrent Adult Soft Tissue Sarcoma, Recurrent Melanoma, Recurrent Skin Cancer, Squamous Cell Carcinoma of the Skin, Stage III Adult Soft Tissue Sarcoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Adult Soft Tissue Sarcoma, Stage IV Melanoma
- Interventions
- isolated limb perfusion, melphalan, quality-of-life assessment
- Drug · Procedure
- Lead sponsor
- Albert Einstein College of Medicine
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Neuroblastoma
- Interventions
- buthionine sulfoximine, melphalan, Peripheral blood stem cell infusion, Filgrastim
- Drug · Procedure · Other
- Lead sponsor
- New Approaches to Neuroblastoma Therapy Consortium
- Other
- Eligibility
- Up to 30 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2016
- U.S. locations
- 8
- States / cities
- Los Angeles, California • San Francisco, California • Chicago, Illinois + 5 more
- Conditions
- Cirrhosis, Hepatic Encephalopathy
- Interventions
- Albumin Infusion
- Drug
- Lead sponsor
- Hunter Holmes Mcguire Veteran Affairs Medical Center
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- Richmond, Virginia
- Conditions
- Fallopian Tubes Cancer, Ovarian Cancer, Peritoneal Cancer
- Interventions
- bevacizumab and the polyvalent vaccine-KLH conjugate + OPT-821
- Biological
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Head and Neck Cancer, Kidney Cancer, Liver Cancer, Lymphoma, Neuroblastoma, Ovarian Cancer, Retinoblastoma, Sarcoma, Testicular Germ Cell Tumor
- Interventions
- filgrastim, carboplatin, thiotepa, topotecan hydrochloride, autologous bone marrow transplantation, bone marrow ablation with stem cell support, in vitro-treated bone marrow transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Up to 21 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1992 – 2005
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Stroke, Muscle Spasticity
- Interventions
- Botox (botulinum toxin)
- Drug
- Lead sponsor
- New York Presbyterian Hospital
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Relapsing Polychondritis
- Interventions
- Methotrexate (MTX), Azathioprine (AZA), Adalimumab, Infliximab, Tocilizumab
- Drug · Biological
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor, Platinum-resistant Ovarian Cancer, Post Anti-PD-1 Melanoma, 2L+ Cervical Cancer, Neoadjuvant Melanoma, Neoadjuvant Non-Small Cell Lung Cancer, Post Anti-PD-(L)1 Non-Small Cell Lung Cancer, Post Anti-PD-(L)1 Small Cell Lung Cancer, Third Line or Later (3L+) HER2+ Breast Cancer, Second or Third Line (2L/3L) Cervical Cancer, Third-line or Later (3L+) Platinum-resistant Ovarian Cancer (PROC)
- Interventions
- TransCon IL-2 β/γ, Pembrolizumab, Chemotherapy drug, TransCon TLR7/8 Agonist, Surgery, Trastuzumab, Trastuzumab emtansine (T-DM1)
- Drug · Procedure
- Lead sponsor
- Ascendis Pharma Oncology Division A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 14
- States / cities
- Los Angeles, California • Springfield, Illinois • Louisville, Kentucky + 10 more
- Conditions
- Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Non-Small Cell Lung Cancer, Hepatocellular Carcinoma
- Interventions
- Ramucirumab, MEDI4736
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 7
- States / cities
- Santa Monica, California • Baltimore, Maryland • St Louis, Missouri + 4 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- LY2605541, Insulin Glargine, Insulin Lispro
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,369 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 48
- States / cities
- Mobile, Alabama • Tucson, Arizona • Little Rock, Arkansas + 45 more
- Conditions
- Leukemia
- Interventions
- CLAG Regimen, Gleevec®
- Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Mild Autonomous Cortisol Secretion (MACS), Adrenalectomy; Status
- Interventions
- Tirzepatide, Standard medical treatment
- Drug · Other
- Lead sponsor
- Alaa Sada
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Refractory Metastatic Colorectal Cancer
- Interventions
- Trifluridine/Tipiracil, Bevacizumab
- Drug
- Lead sponsor
- Taiho Oncology, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 492 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 12
- States / cities
- Phoenix, Arizona • Duarte, California • South Pasadena, California + 9 more
- Conditions
- Cancer of Pancreas
- Interventions
- Bemcentinib, Nab-paclitaxel, Gemcitabine, Cisplatin
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Glioblastoma Multiforme, Glioblastoma - Category
- Interventions
- Bevacizumab, Magnetic Resonance Spectroscopy (MRS), Border Zone Stereotactic Radiosurgery (BZ-SRS)
- Drug · Procedure
- Lead sponsor
- Ajay Niranjan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Metastatic Uveal Melanoma
- Interventions
- RP2, Ipilimumab, Nivolumab
- Biological
- Lead sponsor
- Replimune, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 29
- States / cities
- Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 23 more
- Conditions
- Breast Cancer
- Interventions
- bevacizumab, paclitaxel albumin-stabilized nanoparticle formulation
- Biological · Drug
- Lead sponsor
- Premiere Oncology
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 1
- States / cities
- Santa Monica, California
- Conditions
- Sleep Disturbances
- Interventions
- S-Adenosyl Methionine (SAMe), Propyl Gallate, Gamma-Aminobutyric Acid (GABA), L-Theanine, and Magnesium Glycinate
- Dietary Supplement
- Lead sponsor
- Bonafide Health
- Industry
- Eligibility
- 40 Years to 65 Years · Female only
- Enrollment
- 90 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Harrison, New York